Morning News - Thursday, October 26, 2006
OSI – company delays Q3 results due to revenue understatement
KTO - 3Q profit up 29% on strong sales, company does not change guidance.
RARE - 3Q EPS loss, gives outlook for 4Q, FY06, 1Q07. EPS down (-10c) vs cons 23c. Rev $228.1M vs cons $253.17. Guides 4Q EPS 41c-43c (46c-48c ex-items) vs cons 43c; 4Q SSS 1-2%; FY06 $1.41-$1.43 ($1.68-$1.70 ex-items) vs cons $1.56; 1Q06 EPS of 50c-52c vs cons 54c.
Astrazeneca - key drug NXY-059 showed no efficacy in stroke, did not meet primary outcome.
PYX – 3Q06 EPS beats by 1c, beats on revs, gives guidance. EPS 8c ex-items (6c adj)vs cons 7c. Revs $142.4M vs cons $139.58M. Co sees operating income within middle range of $103-108M and FY06 revs down 2% on reported basis due to divested brands.
Nikkei up .67% to close at 16811.60
Gold Spot: 595 + 7.40
Oil 61.52 + .13
Dollar: euro 1.2666 + .0079; yen 118.60 - .55
KTO - 3Q profit up 29% on strong sales, company does not change guidance.
RARE - 3Q EPS loss, gives outlook for 4Q, FY06, 1Q07. EPS down (-10c) vs cons 23c. Rev $228.1M vs cons $253.17. Guides 4Q EPS 41c-43c (46c-48c ex-items) vs cons 43c; 4Q SSS 1-2%; FY06 $1.41-$1.43 ($1.68-$1.70 ex-items) vs cons $1.56; 1Q06 EPS of 50c-52c vs cons 54c.
Astrazeneca - key drug NXY-059 showed no efficacy in stroke, did not meet primary outcome.
PYX – 3Q06 EPS beats by 1c, beats on revs, gives guidance. EPS 8c ex-items (6c adj)vs cons 7c. Revs $142.4M vs cons $139.58M. Co sees operating income within middle range of $103-108M and FY06 revs down 2% on reported basis due to divested brands.
Nikkei up .67% to close at 16811.60
Gold Spot: 595 + 7.40
Oil 61.52 + .13
Dollar: euro 1.2666 + .0079; yen 118.60 - .55
